B+
Bull case
20%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
CAPR
Capricor TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexB
Base case
35%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
News tone is strongly negative following the advisory committee setback. The RankAlpha price anchor was $4.20 on August 3, but no precise post-vote attribution, analyst revision set, or social-coverage dataset is available. Confidence is therefore limited despite strong primary-source confirmation.
RankAlpha Sentiment Codex - 2026-08-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15catalystPost-advisory regulatory overhangHigh impact
The negative committee vote creates near-term volatility and raises the risk of a CRL, restricted label, or delayed commercialization. Exact analyst revisions and market-reaction attribution are unavailable.
2026-08-22eventFDA PDUFA action on deramiocel BLAHigh impact
The FDA action date remains August 22, 2026. The advisory committee voted 3-9 that available evidence did not support effectiveness for DMD cardiomyopathy; the vote is non-binding and the FDA will consider the full record [#8-K-2026-07-30].
2026-12-31catalystClinical durability and launch optionalityHigh impact
Company-reported five-year HOPE-2 OLE data and prior HOPE-3 results support clinical optionality, while the company reported an operational GMP facility and cash expected to support operations into Q4 2027 [#PR-EARNINGS-2026-06-26][#SEC-8K-2026-05-12]. These benefits matter only if the regulatory path recovers.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology